Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial

BACKGROUND: A high percentage of epithelial ovarian cancers (EOC) express the estrogen receptor (ER), which is an ideal target for endocrine therapy. Letrozole is a proven, potent aromatase inhibitor, extensively tested and used in the treatment of ER positive breast cancer. In addition, it seems a...

Descripción completa

Detalles Bibliográficos
Autores principales: McLaughlin, Pamela M. J., Klar, Maximilian, Zwimpfer, Tibor A., Dutilh, Gilles, Vetter, Marcus, Marth, Christian, du Bois, Andreas, Schade-Brittinger, Carmen, Reuss, Alexander, Bommer, Claudine, Kurzeder, Christian, Heinzelmann-Schwarz, Viola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9074273/
https://www.ncbi.nlm.nih.gov/pubmed/35524184
http://dx.doi.org/10.1186/s12885-022-09555-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9074273/
https://www.ncbi.nlm.nih.gov/pubmed/35524184
http://dx.doi.org/10.1186/s12885-022-09555-8

Ejemplares similares